SMO inhibitors, vismodegib (GDC-0449), sonidegib (NVP-LDE225) and saridegib (IPI-926), have been approved by the FDA for the treatment of glioblastoma and base cell carcinoma [12,13] or for clinical trials in the treatment of pancreatic, breast and colon cancer [14]. Here, SMO is linked to glioblastoma.